1 |
Arafa MA, Rabah DM, Wahdan IH (2012). Awareness of general public towards cancer prostate and screening practice in arabic communities: a comparative multi-center study. Asian Pac J Cancer Prev, 13, 4321-6.
DOI
|
2 |
Baade PD, Yu XQ, Smith DP, et al (2015). Geographic disparities in prostate cancer outcomes--review of international patterns. Asian Pac J Cancer Prev, 16, 1259-75.
DOI
|
3 |
Bashir MN, Ahmad MR, Malik A (2014). Risk factors of prostate cancer: a case-control study in faisalabad, pakistan. Asian Pac J Cancer Prev, 15, 10237-40.
|
4 |
Becker C, Piironen T, Pettersson K, et al (2000). Clinical value of human glandular kallikrein 2 and free and total prostatespecific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/ mL or greater. Urol, 55, 694-9.
DOI
|
5 |
Borgono CA, Diamandis EP (2004). The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer, 4, 876-90.
DOI
|
6 |
Boyle P, Severi G, Giles GG. (2003). The epidemiology of prostate cancer. Urol Clin North Am, 30, 209-17.
DOI
|
7 |
Chiu PK, Wong AY, Hou SM, et al (2011). Effect of body mass index on serum prostate-specific antigen levels among patients presenting with lower urinary tract symptoms. Asian Pac J Cancer Prev, 12, 1937-40.
|
8 |
Choubey VK, Sankhwar SN, Carlus SJ, et al (2015). SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer. Asian Pac J Cancer Prev, 16, 1033-6.
DOI
|
9 |
Daniyal M, Siddiqui ZA, Akram M, et al (2014). Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev, 15, 9575-8.
DOI
|
10 |
El Ezzi AA, Zaidan WR, El-Saidi MA, et al (2014). Association of benign prostate hyperplasia with polymorphisms in vdr, cyp17, and srd5a2 genes among lebanese men. Asian Pac J Cancer Prev, 15, 1255-62.
DOI
|
11 |
Esfahani M, Ataei N, Panjehpour M (2015). Biomarkers for evaluation of prostate cancer prognosis. Asian Pac J Cancer Prev, 16, 2601-11.
DOI
|
12 |
Heidenreich A, Bellmunt J, Bolla M, et al (2011). EAU guidelines on prostate cancer. part 1: screening, diagnosis, and treatment of clinically localized disease. Europ Urol, 59, 61-71.
DOI
|
13 |
Herrala AM, Porvari KS, Kyllonen AP, et al (2001). Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. Cancer, 92, 2975-84.
DOI
|
14 |
Murray NP, Reyes E, Fuentealba C, (2014). Extended use of p504s positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in chile. Asian Pac J Cancer Prev, 15, 9335-9.
DOI
|
15 |
Jansen FH, Roobol M, Jenster G, et al (2009). Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. European Urol, 55, 563-74.
DOI
|
16 |
Madu CO, Lu Y (2010). Novel diagnostic biomarkers for prostate cancer. J Cancer, 6, 150-77.
|
17 |
Martin BJ, Finlay JA, Sterling K, et al (2004). Early detection of prostate cancer in african-american men through use of multiple biomarkers: human kallikrein 2 (hK2), prostatespecific antigen (PSA), and free PSA (fPSA). Prostate Cancer Prostatic Diseases, 7, 132-7.
DOI
|
18 |
Nam RK, Diamandis EP, Toi A, et al (2000). Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol, 18, 1036-42.
|
19 |
Ozbek E, Otunctemur A, Dursun M,(2014). The metabolic syndrome is associated with more aggressive prostate cancer. Asian Pac J Cancer Prev, 15, 4029-32.
DOI
|
20 |
Raaijmakers R, de Vries SH, Blijenberg BG, et al (2007). hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol, 52, 1358-64.
DOI
|
21 |
Salim EI, Moore MA, Al-Lawati JA, et al (2009). Cancer epidemiology and control in the arab world - past, present and future. Asian Pac J Cancer Prev, 10, 3-16.
|
22 |
Stephan C, Jung K, Nakamura T, et al (2006). Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J Urol, 13, 238-43.
DOI
|
23 |
Scorilas A, Plebani M, Mazza S, et al (2003). Serum human glandular kallikrein (hK2) and insulin likegrowth factor1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate, 54, 220-9.
DOI
|
24 |
Shamseddine A, Saleh A, Charafeddine M, et al (2014). Cancer trends in Lebanon: a review of incidence rates for the period of 2003-2008 and projections until 2018. Popul Health Metr, 12, 4.
DOI
|
25 |
Shariat SF, Roehrborn CG (2008). Using biopsy to detect prostate cancer. Rev Urol, 10, 262-80.
|
26 |
Thorek DL, Evans MJ, Carlsson SV, et al (2013). Prostatespecific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thromb Haemost, 110, 484-92.
DOI
|
27 |
Vickers AJ, Cronin AM, Aus G, Pihl CG, et al (2008). A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the european randomized study of prostate cancer screening in Goteborg, Sweden. BMC Med, 6, 19.
DOI
|
28 |
Woo HY, Park H, Kwon MJ, et al (2012). Association of prostate specific antigen concentration with lifestyle characteristics in Korean men. Asian Pac J Cancer Prev, 13, 5695-9.
DOI
|